Additionally, studies suggest that ibrutinib enhances venetoclax efficacy by reducing BCL-XL and MCL-1 levels as it relocates CLL cells from the lymph nodes to peripheral blood, where survival signals are less abundant [64,75]. Here, MCL1 is linked to B-cell chronic lymphocytic leukemia.